Chemistry of Natural Compounds, Vol. 49, No. 6, January, 2014 [Russian original No. 6, November–December, 2013]

SYNTHESIS OF HALO-SUBSTITUTED FRAMEWORK DERIVATIVES OF QUINOPIMARIC ACID

G. F. Vafina,^{*} A. R. Uzbekov, F. Z. Galin, and M. S. Yunusov UDC 547.914.2:547.89.2

6-Chloro-, 6-chloroacetoxy-, and 16-(2-bromoacetyl) framework derivatives were synthesized from a photoadduct of quinopimaric acid.

Keywords: diterpene acids, framework compounds, halo-derivatives.

Natural diterpene acids of the abietane type comprise plant metabolites isolated from sap of conifers and are of definite interest because of their availability and broad spectrum of biological activity [1]. The principal constituent of *Pinus sylvestris* sap is levopimaric acid (30–35%), which is well known to undergo readily a diene-synthesis reaction [2–5]. Data on the pharmacological activity of levopimaric acid derivatives address mainly compounds prepared by a diene-synthesis reaction with quinones [1]. Adducts from a diene synthesis of levopimaric acid with quinones undergo intramolecular cyclization through the action of UV light to form framework γ -diketones and birdcage compounds [6, 7]. The synthesis of various framework derivatives of diene adducts of *p*-benzoquinone is interesting because of their novel interesting physiological properties (treatment of neurodegenerative disorders and antiviral, antitumor, and other properties) [8].

Introduction into quinopimaric acid of functional groups, e.g., halides, that react with amino- and sulfur-containing groups, is especially successful for peripheral design of framework derivatives of it. Natural halo-containing diterpenoids are few in number. However, the variety of biological activity makes them more and more attractive [9].

Therefore, halides were introduced by two methods into quinopimaric acid framework derivatives, i.e., into the framework and diterpene parts of quinopimaric acid 6-hydroxy-framework derivatives 1 and 2. The stereochemistry of the hydroxyl in the C-6 position of 1 and 2 was determined based on the stereochemistry of the C-1 position in 1-hydroxyquinopimaric acid, in which the OH group has the β -orientation [10].



a. POCl₃, Py, 0°C, 99%; b. ClCH₂COCl, CHCl₃, 86%

Institute of Organic Chemistry, Ufa Scientific Center, Russian Academy of Sciences, 450054, Ufa, Prosp. Oktyabrya, 71, e-mail: vafina@anrb.ru. Translated from *Khimiya Prirodnykh Soedinenii*, No. 6, November–December, 2013, pp. 887–890. Original article submitted July 4, 2013.



Fig. 1. General view of 4 with atoms represented as 50% probability thermal ellipsoids.



2: R = OH, $R_1 = H$; **5:** R = OH, $R_1 = Ac$; **6:** R = Cl, $R_1 = Ac$ *a*. Ac_2O ; *b*. (COCl)₂; *c*. CH_2N_2 , CH_2Cl_2 , $-5^{\circ}C$; *d*. 40% HBr

Exchange of the OH by Cl in ketol 1 was carried out using POCl₃ in Py at 0°C and gave a quantitative yield of optically active chloride 3, $[\alpha]_D^{20}$ +66° (*c* 2.0, CHCl₃).

Formation of chloride **3** was proved using NMR spectroscopy and elemental analysis. Thus, the ¹³C NMR spectrum (J-modulation mode) showed that the doublet for C-6-OH at δ_C 72.41 ppm disappeared and a doublet for C-6-Cl at δ_C 56.95 ppm appeared.

Chloro-substituted ester **4** was obtained by the action of chloroacetyl chloride on ketol **1** under reflux in anhydrous CHCl₃. The yield of the 6-chloroacetoxy derivative was 86%. The structure of **4** was confirmed by an x-ray crystal structure analysis (XSA) (Fig. 1).

The ¹³C NMR spectrum (J-modulation mode) of **4** displayed a weak-field shift of the doublet for C-6-O to $\delta_{\rm C}$ 77.13 ppm, the appearance of a triplet for CH₂Cl at $\delta_{\rm C}$ 40.78 ppm, and a singlet for OCO at $\delta_{\rm C}$ 166.14 ppm.

The halogen was introduced into the diterpene part of the molecule *in situ* in four steps. First, ketol **2** was refluxed in acetic anhydride to protect the hydroxy group. Then, oxalyl chloride reacted with acetate **5** to give acid chloride **6**, treatment of which in CH_2Cl_2 with diazomethane in Et_2O at $-5^{\circ}C$ gave diazoketone **7**, which was treated without isolation with HBr solution (40%). The yield of bromoketone **8** was 86% in the last step.

Formation of **8** was proved using NMR spectroscopy and elemental analysis. Thus, the ¹³C NMR spectrum (J-modulation mode) showed that the singlet for the carboxylic C atom disappeared and two new resonances, a singlet for a CO group at δ_C 206.53 ppm and a triplet for CH₂Br at δ_C 31.99 ppm, appeared.

EXPERIMENTAL

PMR and ¹³C NMR spectra were taken in 10–20% solutions in deuterated solvent with solvent resonance or SiMe₄ as internal standard on Bruker AM-300 (300.13 and 75.47 MHz) and Avance III 500 (500.13 and 125.75 MHz) instruments. Chemical shifts are given on the δ -scale. IR spectra were recorded in a thin layer or nujol suspension on a Shimadzu instrument. Elemental analysis was performed on a Euro EA 3000 analyzer. Optical rotation angles were measured on a PerkinElmer 341 polarimeter (λ 589 nm) at 20°C.

The XSA was carried out on a Bruker Smart Apex2 CCD diffractometer at 100 K (λ Mo K α -radiation, $2\theta_{max} = 64^\circ$). The dataset of measured intensities was processed using the SAINT and SADABS programs included in the Apex2 program set [11]. The structure was solved by direct methods and refined by anisotropic full-matrix least-squares methods for non-hydrogen atoms over F^2_{hkl} . All calculations were performed on an IBM PC using the SHELXTL program set [12].

The course of reactions was monitored by TLC on Sorbfil PTSKh-AF-A plates. Compounds were detected by spraying plates with H_2SO_4 solution (5%) with subsequent heating to 100–120°C. The eluents were solvent systems CHCl₃:MeOH (50:1, 10:1, 5:1). Column chromatography was carried out over standard silica gel 60 (0.063–0.2 mm, 70–230 mesh) (Macherey-Nagel, Germany). Analytical data of all synthesized compounds agreed with those calculated.

Framework quinopimaric acid derivatives 1 and 2 were synthesized as before [13]. The physical and spectral characteristics of 1 and 2 corresponded with the literature data.

Methyl (7*S*,8*S*,16*R*,20*R*)-16,20-Dimethyl-4-isopropyl-6-chloro-9-oxoheptacyclo[10.8.0. 3,7 .0^{4,11}.0^{5,10}.0^{8,12}.0^{15,20}] eicosane-16-carboxylate (3). C₂₇H₃₇ClO₃. Compound 1 (0.7 g, 1.7 mmol) in anhydrous Py (23 mL) at 0°C was stirred, treated dropwise with POCl₃ (1.1 mL, 12 mmol) and stirred at 0°C for 0.5 h and at room temperature for 7 h. The solvent was distilled at reduced pressure. The residue was treated with CHCl₃ (20 mL) and washed with HCl solution (1%) and H₂O. The organic phase was dried over Na₂SO₄. The solvent was removed at reduced pressure to afford **3** (0.72 g, 99.9%), mp 114–118°C, $[\alpha]_{D}^{20}$ +66° (*c* 2.0; CHCl₃). IR spectrum (ν, cm⁻¹): 1726, 1460, 1377, 1244, 1194, 1142, 1103, 1053, 974, 754. ¹³C NMR spectrum (CDCl₃ + CD₃OD, δ, ppm): 15.01 (q, Me), 16.25 (q, Me), 16.66 (q, Me), 16.85 (t, C-18), 17.15 (t, C-14), 18.25 (q, Me), 20.81 (t, C-2), 26.31 (d, C-21), 33.29 (t, C-13), 34.17 (d, C-10), 36.40 (s, C-20), 37.27 (t, C-17), 37.60 (t, C-19), 38.33 (s, C-12), 38.80 (d, C-5), 41.45 (d, C-7), 42.35 (d, C-11), 44.83 (d, C-3), 45.27 (d, C-15), 46.86 (s, C-16), 49.30 (d, C-1), 50.61 (s, C-4), 51.66 (q, COO<u>Me</u>), 56.95 (d, C-6), 57.05 (d, C-8), 179.15 (s, COO), 218.45 (s, C=O).

Methyl $(16R,20R)-6-[(2-Chloroacetyl)oxy]-4-isopropyl-16,20-dimethyl-9-oxoheptacyclo[10.8.0.0^{3,7}.0^{4,11}.0^{5,10}.0^{8,12}.0^{15,20}]eicosane-16-carboxylate (4).<math>C_{29}H_{39}ClO_{5.}$ Methyl ester of 1 (1.0 g, 2.43 mmol) inanhydrous CHCl₃ (20 mL) was treated with chloroacetyl chloride (1 mL) and refluxed for 15 h.The solvent was evaporated.The residue was purified by column chromatography over silica gel using CHCl₃-MeOH (50:1).Yield 86%, mp 204-205°C(CHCl₃), $[\alpha]_D^{20} +73°$ (c 2.0; CHCl₃).IR spectrum (v, cm⁻¹): 1738, 1721, 1462, 1375, 1275, 1254, 1165, 1140, 1103, 1028,988, 785.¹³C NMR spectrum (CDCl₃, δ , ppm): 15.34 (q, Me), 16.64 (q, Me), 17.07 (q, Me), 17.21 (t, C-18), 17.56 (t, C-14),18.57 (q, Me), 21.11 (t, C-2), 26.62 (d, C-21), 33.60 (t, C-13), 35.01 (d, C-10), 36.69 (t, C-17), 37.57 (s, C-20), 37.90 (t, C-19),38.37 (s, C-12), 39.10 (d, C-5), 40.36 (d, C-7), 40.78 (t, CH₂Cl), 42.55 (d, C-11), 43.74 (d, C-3), 45.41 (d, C-15), 47.10 (s, C-16), 49.57 (d, C-1), 50.77 (s, C-4), 51.94 (q, COOMe), 57.10 (d, C-8), 77.13 (d, C-6), 166.14 (s, OCO), 178.99 (s, COO),216.31 (s, C=O).A CIF file containing complete information on the structure was deposited in the CCDC (No. 948487) (http://www.ccdc.cam.ac.uk/deposit).

 $(7 S, 8 S, 16 R, 20 R) - 6 - (A c e t y l o x y) - 4 - i s o p r o p y l - 16, 20 - d i m e t h y l - 9 - o x o h e p t a c y c l o [10.8.0.0^{3,7}.0^{4,11}.0^{5,10}.0^{8,12}.0^{15,20}]eicosane-16-carboxylate (5). C₂₉H₄₀O₅. A mixture of 2 (1.3 g, 3.15 mmol) in Ac₂O (6 mL) was refluxed for 1 h and evaporated to dryness. The residue was dissolved in CHCl₃ (30 mL), washed with H₂O (2 × 10 mL), and dried over Na₂SO₄. The solvent was removed at reduced pressure to afford the acetate (1.36 g), quantitative yield, mp 68–69°C, <math>[\alpha]_D^{20}$ +65° (*c* 2.1; CHCl₃). IR spectrum (v, cm⁻¹): 1747, 1732, 1462, 1377, 1236, 1194, 1142, 1103, 1051, 752. ¹³C NMR spectrum (CDCl₃, δ , ppm): 15.16 (q, Me), 16.30 (q, Me), 16.76 (q, Me), 16.81 (t, C-18), 17.49 (t, C-14), 18.41 (q, Me), 20.94 (q, MeCO), 21.01 (t, C-2), 26.43 (d, C-21), 33.48 (t, C-13), 34.86 (d, C-10), 35.69 (s, C-20), 37.37 (t, C-17), 37.57 (t, C-19), 38.24 (s, C-12), 38.91 (d, C-5), 40.36 (d, C-7), 42.37 (d, C-11), 43.64 (d, C-3), 45.44 (d, C-15), 47.94 (s, C-16), 48.94 (d, C-1), 50.53 (s, C-4), 57.05 (d, C-8), 75.02 (d, C-6), 169.78 (s, COMe), 174.00 (s, COO), 216.46 (s, C=O).

(16R, 20R) - 16 - (2 - Diazoacetyl) - 6 - (acetyloxy) - 4 - is opropyl - 16, 20 - dimethyl - 9 - oxoheptacyclo[10.8.0.0^{3,7}.0^{4,11}.0^{5,10}.0^{8,12}.0^{15,20}]eicosane (7). C₂₉H₃₈N₂O₄. A suspension of 5 (0.55 g, 1.25 mmol) in

anhydrous CH_2Cl_2 (20 mL) was stirred under Ar and treated with oxalyl chloride (1 mL) and DMF (5 drops). When the reaction was finished, the solvent and excess of oxalyl chloride were evaporated in vacuo (the bath temperature should not exceed 30°C). Acid chloride **6** was used without further purification. A solution of **6** in anhydrous $CHCl_3$ (20 mL) was added dropwise to a stirred and cooled (-5°C) solution of diazomethane in Et₂O that was prepared from nitrosomethylurea (4.5 g) and stirred at -5°C for 0.5 h. The solvent was distilled at reduced pressure. The yield was quantitative, mp 70–73°C. IR spectrum (v, cm⁻¹): 2100 (CN₂), 1798 (CO), 1757 (CO), 1724 (CO).

 $(16R, 20R) - 6 - (Acetyloxy) - 16 - (2-bromoacetyl) - 4 - isopropyl - 16, 20 - dimethyl - 9 - oxoheptacyclo [10.8.0.0^{3,7}.0^{4,11}.0^{5,10}.0^{8,12}.0^{15,20}] eicosane (8). C₂₉H₃₉BrO₄. A solution of 7 (0.64 g, 1.34 mmol) in CH₂Cl₂ (10 mL) was stirred and treated dropwise with HBr solution (40%, 1.34 mL). When gas evolution stopped, the solution was stirred for 1 h and diluted with CHCl₃ (30 mL). The organic layer was separated, washed with NaHCO₃ solution (5%, 10 mL), and evaporated. The residue was purified using column chromatography over silica gel and CHCl₃:MeOH (50:1). Yield 86%, mp 69–70°C, <math display="inline">[\alpha]_D^{20} + 53^{\circ} (c 1.1; CHCl_3)$. IR spectrum (v, cm⁻¹): 1744, 1715, 1462, 1377, 1236, 1043, 752. ¹H NMR (CDCl₃, δ , ppm, J/Hz): 0.71 (1H, m, H-18e), 0.72 (3H, d, ³J = 6.4, Me), 0.86 (3H, s, 20-Me), 0.88 (2H, m, H-2e, H-19e), 1.05 (1H, m, H-13e), 1.15 (3H, d, ³J = 6.4, Me), 1.16 (3H, s, 16-Me), 1.18 (1H, m, H-13a), 1.30 (1H, m, H-2a), 1.49 (2H, m, H-14e, H-18a), 1.60 (2H, m, H-1, H-19a), 1.72 (2H, m, H-8, H-14a), 1.90 (3H, s, COMe), 1.92 (1H, m, H-21), 2.18 (1H, s, H-10), 2.38 (1H, m, H-11), 2.50 (2H, s, H-3, H-5), 2.62 (1H, d, J = 8.8, H-7), 4.10 (2H, dd, J = 17.7, 13.3, CH₂Br), 4.70 (1H, s, H-6). ¹³C NMR (CDCl₃, δ , ppm): 15.28 (q, Me), 16.22 (q, Me), 16.74 (q, Me), 16.89 (t, C-18), 17.48 (t, C-14), 18.39 (q, Me), 20.94 (q, MeCO), 21.06 (t, C-2), 26.38 (d, C-21), 31.99 (t, CH₂Br), 33.36 (t, C-13), 34.81 (d, C-10), 36.04 (s, C-20), 37.46 (t, C-17), 37.54 (t, C-19), 38.19 (s, C-12), 38.91 (d, C-5), 40.29 (d, C-7), 42.33 (d, C-11), 43.57 (d, C-3), 45.51 (d, C-15), 48.65 (d, C-1), 50.48 (s, C-16), 52.39 (s, C-4), 57.01 (d, C-8), 74.95 (d, C-6), 169.71 (s, COMe), 206.53 (s, COCH₂), 216.37 (s, C=O).

ACKNOWLEDGMENT

The work was supported financially by a grant of the RF President for leading scientific schools No. NSh-7014.2012.3 and basic research programs of the RAS Presidium No. 8P. We thank K. Yu. Suponitskii (Inst. Organoelem. Compd., RAS) for performing the XSA of **4**.

REFERENCES

- 1. G. A. Tolstikov, T. G. Tolstikova, E. E. Shul'ts, S. E. Tolstikov, and M. V. Khvostov, *Resinous Acids of Russian Conifers*. *Chemistry, Pharmacology* [in Russian], Geo, Novosibirsk, 2011, 395 pp.
- G. A. Tolstikov, E. E. Shul'ts, T. Sh. Mukhametzyanova, I. P. Baikova, and L. V. Spirikhin, *Zh. Org. Khim.*, 29 (4), 698 (1993).
- S. V. Chernov, E. E. Shul'ts, Yu. V. Gatilov, I. Yu. Bagryanskaya, and G. A. Tolstikov, *Zh. Org. Khim.*, 33 (5), 678 (1997).
- 4. B. A. Arbuzov and A. G. Khismatullina, Izv. Akad. Nauk SSSR, Ser. Khim., 12, 2126 (1959).
- 5. G. F. Vafina, R. R. Fazlyev, F. Z. Galin, and L. V. Spirikhin, Zh. Org. Khim., 45 (4), 515 (2009).
- 6. W. Herz, R. C. Blackstone, and M. G. Nair, J. Org. Chem., 32, 2992 (1967).
- 7. G. F. Vafina, R. R. Fazlyev, A. N. Lobov, L. V. Spirikhin, and F. Z. Galin, Zh. Org. Khim., 46, 1364 (2010).
- W. J. Geldenhuys, S. F. Malan, J. R. Bloomquist, A. P. Marchland, and C. J. Van der Schyf, *Med. Res. Rev.*, 25 (1), 21 (2005).
- 9. V. M. Dembitskii and G. A. Tolstikov, *Natural Halogenated Organic Compounds* [in Russian], Geo, Novosibirsk, 2003, 366 pp.
- 10. G. F. Vafina, A. R. Uzbekov, A. N. Lobov, L. V. Spirikhin, and M. S. Yunusov, Chem. Nat. Compd., 49, 651 (2013).
- 11. APEX2 and SAINT, Bruker AXS Inc., Madison, Wisconsin, USA, 2005.
- 12. G. M. Sheldrick, Acta Crystallogr. Sect. A: Found. Crystallogr., 64, 112 (2008).
- 13. G. F. Vafina, A. R. Uzbekov, L. V. Spirikhin, and M. S. Yunusov, Chem. Nat. Compd., 49, 645 (2013).